Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis | oneAMYLOIDOSISvoice
recruiting

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

key information

study id #: NCT04754945

condition: AL Amyloidosis

status: Recruiting

purpose:

This phase I trial studies the side effects of isatuximab and to see how well it works in treating patients with high risk immunoglobulin light chain amyloidosis (AL amyloidosis). Isatuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.

intervention: Bortezomib, Cyclophosphamide, Dexamethasone, Isatuximab

results: https://clinicaltrials.gov/ct2/show/results/NCT04754945

last updated: September 17, 2021

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close